DBV Technologies (DBVT) Accounts Payables (2015 - 2026)
DBV Technologies (DBVT) posted Accounts Payables of $39.4 million for Q2 2026, little changed sequentially from $39.5 million in Q1 2026, and down 3.41% YoY from $40.8 million in Q2 2025.
DBV Technologies (DBVT) Accounts Payables (2015 - 2026) Analysis & Trends
DBV Technologies has reported Accounts Payables for 12 years, with the latest figure at $39.4 million in Q2 2026.
- Quarterly Accounts Payables fell 3.41% year-over-year to $39.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $39.4 million (down 3.41% YoY) and the FY2025 annual result came in at $40.9 million, up 85.64% from the prior year.
- Accounts Payables was little changed at $39.4 million in Q2 2026 per DBVT's latest filing, from $39.5 million in the prior quarter.
- Over five years, Accounts Payables peaked at $40.9 million in Q4 2025 and troughed at $11.4 million in Q1 2022.
- A 5-year average of $25.2 million and a median of $21.0 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2025: Accounts Payables slumped 33.54% in 2022, then surged 105.83% in 2025.
- Over 5 years, Accounts Payables stood at $14.5 million in 2022, then soared by 61.0% to $23.3 million in 2023, then slipped by 5.45% to $22.0 million in 2024, then jumped by 85.64% to $40.9 million in 2025, then fell by 3.67% to $39.4 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $39.4 million, $39.5 million, and $40.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 39.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.40 Mn |
| Mar 31, 2026 | 39.50 Mn |
| Dec 31, 2025 | 40.90 Mn |
| Sep 30, 2025 | 39.82 Mn |
| Jun 30, 2025 | 40.79 Mn |
| Mar 31, 2025 | 34.15 Mn |
| Dec 31, 2024 | 22.03 Mn |
| Sep 30, 2024 | 22.50 Mn |
| Jun 30, 2024 | 19.82 Mn |
| Mar 31, 2024 | 18.08 Mn |
| Dec 31, 2023 | 23.30 Mn |
| Sep 30, 2023 | 16.65 Mn |
| Jun 30, 2023 | 19.09 Mn |
| Mar 31, 2023 | 19.94 Mn |
| Dec 31, 2022 | 14.47 Mn |
| Sep 30, 2022 | 15.37 Mn |
| Jun 30, 2022 | 16.34 Mn |
| Mar 31, 2022 | 11.42 Mn |
| Dec 31, 2021 | 11.43 Mn |
| Sep 30, 2021 | 12.17 Mn |